

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – UPDATE ON THE LICENSING IN AND RESEARCH AND DEVELOPMENT OF AN INVESTIGATIONAL ANTICOAGULANT

This announcement is made by the board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that, in December 2017, the Group had successfully entered into an agreement with GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, pursuant to which the Group is granted exclusive rights to develop and commercialise GCC-4401C, for the greater China and South East Asian market.

GCC-4401C is GC Pharma’s investigational oral Factor Xa inhibitor anticoagulant currently completed Phase I clinical development in the U.S. for the prevention and treatment of thromboembolic disease. It directly inhibits the activity of Factor Xa, an important validated target in the blood coagulation pathway, to prevent thrombosis. GCC-4401C has the potential to become the best in class of active factor Xa inhibitor available, as it shows similar efficacy but less bleeding side effect in Pre-clinical study and Phase I clinical study.

The Group is currently the market leader in anti-thrombotic area in China, including Livaracine, its proprietary low molecular weight heparin. It has a robust pipeline of anti-thrombotic, such as a Phase II anti-platelet drug, Anfibatide, a Phase III Warfarin like anticoagulant, Tecarfarin and a synthetic anti-thrombotic agent, Fondaparinux. The Factor Xa inhibitor anticoagulant, GCC-4401C, complements the group’s existing products and pipelines which can further enhance the Group’s market position in anti-thrombotic area.

China and the surrounding Asian markets represent a significant opportunity for oral Factor Xa inhibitor, because of the increasing incidence of cardiovascular disease. According to a news report from Liaoshen Evening News, there are more than 1.5 million new cases of thrombosis in China per year.

The Group is fully integrated with solid infrastructures in drug development, clinic, perspectives and currently markets 14 products in the PRC. The Group focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology, ophthalmology and others. It has more than 50 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US, European and Japanese companies.

By order of the Board of
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 14 February 2018

** For identification purpose only*

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.